362 related articles for article (PubMed ID: 28103079)
1. ADHD Treatment in Primary Care: Demographic Factors, Medication Trends, and Treatment Predictors.
Hauck TS; Lau C; Wing LLF; Kurdyak P; Tu K
Can J Psychiatry; 2017 Jun; 62(6):393-402. PubMed ID: 28103079
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.
Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
Pediatrics; 2002 May; 109(5):733-9. PubMed ID: 11986429
[TBL] [Abstract][Full Text] [Related]
3. Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom.
Houghton R; Liu C; Bolognani F
Autism Res; 2018 Dec; 11(12):1690-1700. PubMed ID: 30380202
[TBL] [Abstract][Full Text] [Related]
4. Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population.
Radigan M; Lannon P; Roohan P; Gesten F
J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):44-56. PubMed ID: 15741785
[TBL] [Abstract][Full Text] [Related]
5. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
[TBL] [Abstract][Full Text] [Related]
6. National Patterns of Commonly Prescribed Psychotropic Medications to Young People.
Sultan RS; Correll CU; Schoenbaum M; King M; Walkup JT; Olfson M
J Child Adolesc Psychopharmacol; 2018 Apr; 28(3):158-165. PubMed ID: 29376743
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
8. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.
Zito JM; Safer DJ; dosReis S; Magder LS; Gardner JF; Zarin DA
Arch Pediatr Adolesc Med; 1999 Dec; 153(12):1257-63. PubMed ID: 10591302
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
10. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
Song I; Lee MS; Lee EK; Shin JY
Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
[TBL] [Abstract][Full Text] [Related]
11. Prescribing for young people with attention deficit hyperactivity disorder in UK primary care: analysis of data from the Clinical Practice Research Datalink.
Newlove-Delgado T; Hamilton W; Ford TJ; Stein K; Ukoumunne OC
Atten Defic Hyperact Disord; 2019 Sep; 11(3):255-262. PubMed ID: 30730035
[TBL] [Abstract][Full Text] [Related]
12. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study.
Perry BA; Archer KR; Song Y; Ma Y; Green JK; Elefteriou F; Dahir KM
Osteoporos Int; 2016 Jul; 27(7):2223-2227. PubMed ID: 26928186
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.
Furu K; Karlstad Ø; Zoega H; Martikainen JE; Bahmanyar S; Kieler H; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):373-379. PubMed ID: 27911044
[TBL] [Abstract][Full Text] [Related]
14. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.
Brikell I; Wimberley T; Albiñana C; Pedersen EM; Vilhjálmsson BJ; Agerbo E; Demontis D; Børglum AD; Schork AJ; LaBianca S; Werge T; Mors O; Hougaard DM; Thapar A; Mortensen PB; Dalsgaard S
Am J Psychiatry; 2021 Sep; 178(9):854-864. PubMed ID: 34154395
[TBL] [Abstract][Full Text] [Related]
15. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
Mac Avin M; Teeling M; Bennett KE
BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
[TBL] [Abstract][Full Text] [Related]
16. Psychotropic medicine prescriptions in Italian youths: a multiregional study.
Piovani D; Clavenna A; Cartabia M; Bonati M
Eur Child Adolesc Psychiatry; 2016 Mar; 25(3):235-45. PubMed ID: 26016693
[TBL] [Abstract][Full Text] [Related]
17. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.
Comer JS; Olfson M; Mojtabai R
J Am Acad Child Adolesc Psychiatry; 2010 Oct; 49(10):1001-10. PubMed ID: 20855045
[TBL] [Abstract][Full Text] [Related]
18. Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004.
Byrd HC; Curtin C; Anderson SE
Pediatr Obes; 2013 Dec; 8(6):445-53. PubMed ID: 23325553
[TBL] [Abstract][Full Text] [Related]
19. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
[TBL] [Abstract][Full Text] [Related]
20. Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.
Winterstein AG; Soria-Saucedo R; Gerhard T; Correll CU; Olfson M
J Clin Psychiatry; 2017 Jul; 78(7):e744-e781. PubMed ID: 28686819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
